Business Standard

Will pharma stocks continue their dream rally in FY25?

PRESCRIPTION FOR CAUTION: Analysts sound alarm on valuations after past year's recovery

pharma medicine drugs
Web Exclusive Premium

Shivam Tyagi New Delhi

Listen to This Article

Stocks in the pharmaceutical (pharma) sector have had a dream run so far in 2023-24 (FY24), with the National Stock Exchange Nifty Pharma Index surging 58.2 per cent in this period against a dip of 11 per cent in 2022-23 (FY23), reveals Ace Equity data. The index has also outperformed the Nifty50, which grew by 28.7 per cent in the current financial year.

Among stocks, Orchid Pharma gave a handsome return of 210 per cent, followed by Lupin’s 157 per cent jump so far in 2023-24 (FY24).

Others like Suven Life Sciences, Venus Remedies, and Aurobindo Pharma saw 127 per

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 06 2024 | 2:09 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com